Checkpoint-checkpoint combinations in cancer: from mechanistic rationale to translational impact

Our plain-English summary of Checkpoint-checkpoint combinations in cancer: from mechanistic rationale to translational impact, by A. Mazzocca, S. Calagna, E.C. Mingo, et al (Journal of Translational Medicine, 2026).

The study

• Authors: A. Mazzocca, S. Calagna, E.C. Mingo, S. Cavaliere, M. Iuliani, A.L. D'Amato, L. Scarpato, F. Pantano, G. Tonini, B. Vincenzi, A. Cortellini, P.A. Ascierto
• Journal: Journal of Translational Medicine
• Published: 2026;24(1)
• Type of article: Review
• Read it: PubMed · Publisher · Free full text

Abstract

Background: Immune checkpoint inhibitors have reshaped the treatment of several cancers, producing durable responses in a subset of patients. However, most individuals either fail to respond or eventually develop resistance. Tumor immune escape results from heterogeneous and often overlapping mechanisms, including impaired antigen presentation, limited T-cell infiltration, co-expression of multiple inhibitory receptors, and suppressive tumor microenvironmental signals. These limitations have driven the development of combination strategies aimed at restoring more effective and sustained antitumor immunity.

Main Body: Among combination approaches, dual immune checkpoint blockade represents the most established strategy. The combination of CTLA-4 and PD-1 inhibitors targets complementary phases of the immune response: early T-cell priming in lymphoid organs and effector function within the tumor microenvironment. Long-term clinical data across melanoma, lung cancer, renal cell carcinoma, mesothelioma, and hepatocellular carcinoma support the ability of this approach to induce durable survival in a meaningful proportion of patients, albeit with increased immune-related toxicity. Building on this foundation, next-generation checkpoint combinations aim to counteract adaptive resistance and T-cell exhaustion. In particular, LAG-3, TIM-3, and TIGIT are frequently co-expressed with programmed death-1 on dysfunctional T cells. Emerging checkpoints such as VISTA, B7-H3, and BTLA further expand the landscape, particularly by modulating myeloid-driven suppression and advanced T-cell dysfunction. In parallel, bispecific antibodies integrating dual checkpoint targeting within a single molecule may enhance coordinated pathway inhibition and tumor localization.

Conclusion: Immune checkpoint-based combinations represent an evolving strategy of immune restoration. Future advances will depend on biologically informed trial design, dynamic biomarkers, and rational optimization of dose and sequencing to maximize durable benefit while maintaining acceptable toxicity.

© 2026. The Author(s).

In plain English

This article was a narrative review, not a new study. The authors summarized published laboratory and clinical research on combining immune checkpoint inhibitor drugs to treat cancer. The combinations covered were CTLA-4 plus PD-1 blockers, newer targets such as LAG-3, TIM-3, TIGIT, VISTA, B7-H3 and BTLA, and single 'bispecific' antibodies that act on two targets. All trial results described came from other studies. In the CheckMate 743 trial in unresectable malignant pleural mesothelioma, nivolumab plus ipilimumab gave a 2-year overall survival rate of 41%, compared with 27% for chemotherapy. The review described CTLA-4 plus PD-1 combinations as producing durable survival in some patients across several cancers, but with more immune-related side effects. For TIGIT combinations, it reported encouraging phase II results in non-small-cell lung cancer. A later phase III trial did not meet its primary endpoints, and trials in other tumors were disappointing. The authors stated that much of the evidence on newer checkpoints and bispecific antibodies was preliminary or hypothesis-generating. The authors concluded that checkpoint-based combinations are an evolving strategy of immune restoration, and that progress will depend on biologically informed trial design and dynamic biomarkers.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: narrative review of published preclinical and clinical studies of immune checkpoint-based combination treatments for cancer
• Who was studied: No study population of its own; the review covered published trials and laboratory studies in several cancers, including melanoma, lung cancer, renal cell carcinoma, malignant pleural mesothelioma and hepatocellular carcinoma
• Exposure: Not an asbestos exposure study; the 'exposures' reviewed were cancer drug combinations: CTLA-4 plus PD-1/PD-L1 inhibitors, PD-1 combined with LAG-3, TIM-3 or TIGIT blockers, emerging targets (VISTA, B7-H3, BTLA), and bispecific checkpoint antibodies
• Main results:
  • Reporting the CheckMate 743 trial (another study) in unresectable malignant pleural mesothelioma: nivolumab plus ipilimumab achieved a 2-year overall survival rate of 41% compared with 27% for chemotherapy
  • The review's table listed CheckMate 743 3-year results: median overall survival 18.1 months (rate 23%) with nivolumab plus ipilimumab versus 14.1 months (rate 15%) with chemotherapy
  • Reporting the CheckMate-067 trial (another study) in advanced melanoma: 10-year melanoma-specific survival was 52% for nivolumab plus ipilimumab, 44% for nivolumab and 23% for ipilimumab alone
  • The authors described CTLA-4 plus PD-1 combination data as showing durable survival in a proportion of patients, with increased immune-related toxicity
  • The review reported encouraging results for tiragolumab plus atezolizumab (a TIGIT plus PD-L1 combination) in the phase II CITYSCAPE trial in non-small-cell lung cancer
  • The subsequent phase III SKYSCRAPER-01 trial of the same combination in PD-L1-high, previously untreated metastatic non-small-cell lung cancer did not meet its primary endpoints of improved progression-free and overall survival
  • The review reported that phase II and III trials of TIGIT plus PD-1/PD-L1 blockade in tumors other than non-small-cell lung cancer gave disappointing results
  • The review listed an ongoing phase III trial (eVOLVE-Meso) in unresectable pleural mesothelioma comparing the bispecific volrustomig plus chemotherapy with chemotherapy or nivolumab plus ipilimumab
  • A LAG-3 plus PD-1 combination (ieramilimab plus spartalizumab) was tested in a multi-cohort trial that included mesothelioma and showed modest antitumor activity overall
• The authors' conclusion: The authors concluded that immune checkpoint-based combinations are an evolving strategy of immune restoration, and that future advances will depend on biologically informed trial design, dynamic biomarkers, and optimization of dose and sequencing
• Limitations the authors state:
  • The authors stated that, for the emerging checkpoints VISTA, B7-H3 and BTLA, their interpretations are hypotheses rather than definitive conclusions
  • The authors stated that none of the bispecific checkpoint antibodies has yet shown a randomized survival benefit over standard dual checkpoint combinations
  • The authors stated that the concepts about which patients benefit from TIGIT blockade come largely from preclinical models and post-hoc analyses and are hypothesis-generating

Topics

Medical terms in this study, explained in our Lexicon: checkpoint inhibitors, CTLA-4, Tumor Microenvironment, Lung Cancer, Carcinoma, Mesothelioma, Biomarker.

Related studies

• Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations — N. Principe, W.J. Aston, et al. (2022)
• Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review — F. Petrelli, F. Consoli, et al. (2021)
• Characterizing soluble immune checkpoint molecules and TGF-β1,2,3 in pleural effusion of malignant pleural mesothelioma — R. Okita, T. Senoo, et al. (2024)
• Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study — A. Gault, L. Hogarth, et al. (2024)
• Translational advances in pleural malignancies — G.T. Stathopoulos (2011)
• Bedside to bench and back again-translational research in interventional pulmonology — B. Iqbal, H.J. Choi, et al. (2025)

Browse more research in Journal of Translational Medicine, or return to medical research.